Broadfin Capital’s Merck MRK Stock Holding History

Broadfin Capital’s Portfolio MRK Stock Details MRK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-137,183	Closed	-$7.13M	–	53
2018 Q1	$7.13M	Buy	+137,183	New	+$7.41M	1.11%	26

Other funds holding MRK

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Broadfin Capital's MRK Position: Q2 2018 in Review

Broadfin Capital sold out of Merck (MRK) in Q2 2018, closing a stake of 137,183 shares — an estimated $7.13M sold.

Broadfin Capital first reported a position in MRK in Q1 2018 and held it in 1 quarter. The position peaked at $7.13M in Q1 2018. 2,017 funds tracked by Wall St. Rank hold MRK as of Q2 2018.

Broadfin Capital reported no remaining Merck position as of Q2 2018 after selling out during the quarter.
Broadfin Capital sold 137,183 Merck shares in Q2 2018, an estimated $7.13M.
Broadfin Capital first reported a position in Merck in Q1 2018 and held it in 1 quarter.
Broadfin Capital's Merck position peaked at $7.13M in Q1 2018.
2,017 funds tracked by Wall St. Rank held Merck as of Q2 2018.

Based on Broadfin Capital's 13F filing for Q2 2018, filed 14 Aug 2018.